RADIONUCLIDE STENTS FOR ESOPHAGEAL CARCINOMA

癌症引起的食道梗阻会使人虚弱 吞咽困难。吞咽困难的快速安全缓解通常是可能的。 用内窥镜植入可膨胀金属送去。一位少校 这些假体的并发症是由于肿瘤植入或闭塞 过度生长。目前的提案涉及离子注入一种 放射性核素介入金属支架预防肿瘤侵袭 和再狭窄。低强度(小于5微居里)45钙贝塔 发射器将发射聚焦的辐射以有效控制肿瘤 并为不能手术的患者提供合理的姑息治疗 食道癌。这种创新方法在以下方面很有效 提高患者生活质量，降低医疗成本 与并发症和额外干预的需要有关。 建议的商业应用：超过10,000个 晚期食道狭窄患者的支架置入术 在美国，每年要额外使用15,000个支架 每年在国际上。释放β射线的食道支架将 提供局部放射以防止随后的肿瘤生长和 消除了重复住院和额外干预的需要。 贝塔发射的ESS成本效益高，并将在商业上取得成功。

Esophageal obstruction due to cancer can produce debilitating dysphagia. Rapid and safe palliation of dysphagia is usually possible with endoscopic implantation of expandable metal sent. A major complication of these prosthesis is occlusion due to tumor ingrowth or overgrowth. The current proposal addresses ion implantation of a radioactive nuclide into the metallic stent to prevent tumor ingrowth and restenosis. Low intensity (less than 5 microcuries) 45 Ca beta emitter will deliver focused radiation to effectively control tumor ingrowth and provide a reasonable palliative care for inoperable esophageal carcinoma. This innovative approach is effective in improving the quality of life of patients and reducing health care costs associated with complications and the need for additional intervention. PROPOSED COMMERCIAL APPLICATION: There are more than 10,000 stents placed in terminal patients suffering from esophagus strictures per year in the U.S.(11) An additional 15,000 stents are used internationally each year. Beta emitting esophageal stents (ES) will deliver local radiation to prevent subsequent tumor ingrowth and eliminate the need for repeat hospitalization and additional intervention. Beta emitting ESs are cost effective and will be a commercial success.